Actively Recruiting
Phase III Study Comparing Fruquintinib Plus Sintilimab With Chemotherapy as Second-Line Treatment for Advanced Endometrial Cancer in Women Aged 18 to 75
Led by Hutchmed · Updated on 2025-01-07
412
Participants Needed
17
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of fruquintinib HMPL-013 combined with sintilimab IBI308 compared to chemotherapy in treating advanced endometrial cancer. This Phase III randomized, open-label, multicenter study focuses on patients whose cancer has progressed after first-line platinum-based chemotherapy. The purpose is to determine if this combination therapy offers benefits over physician-chosen chemotherapy options such as paclitaxel or doxorubicin. Participants will be randomly assigned to one of two groups. One group will receive fruquintinib orally once daily for two weeks followed by a one-week break, plus sintilimab intravenously every three weeks. The other group will receive chemotherapy with either paclitaxel weekly for three weeks followed by a one-week break or doxorubicin every three weeks. Treatment continues until disease progression confirmed by an independent review committee or other discontinuation criteria are met. Throughout the study, participants will undergo regular assessments including scans and tests to monitor disease progression and response. Researchers will track progression-free survival and overall survival for up to approximately four years. Additional evaluations include tumor response rates, duration of response, disease control, quality of life questionnaires, and safety monitoring. Blood samples will be collected to measure drug levels. The total study duration for each participant may last up to several years with ongoing follow-up.
CONDITIONS
Brief Title
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Research Team
P
Panfeng Tan
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here